Volume | 47,224 |
|
|||||
News | - | ||||||
Day High | 1.9565 | Low High |
|||||
Day Low | 1.70 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cocrystal Pharma Inc | COCP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.72 | 1.70 | 1.9565 | 1.7292 | 1.75 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
351 | 47,224 | $ 1.79 | $ 84,697 | - | 1.325 - 3.285 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:00:34 | 21 | $ 1.82 | USD |
Cocrystal Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
17.6M | 10.17M | - | 2.6M | -17.98M | -1.77 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cocrystal Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COCP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.57 | 1.9565 | 1.53 | 1.70 | 28,914 | 0.1592 | 10.14% |
1 Month | 1.50 | 1.9565 | 1.35 | 1.59 | 15,486 | 0.2292 | 15.28% |
3 Months | 1.50 | 1.9565 | 1.325 | 1.52 | 15,942 | 0.2292 | 15.28% |
6 Months | 1.79 | 1.99 | 1.325 | 1.63 | 16,971 | -0.0608 | -3.40% |
1 Year | 2.90 | 3.285 | 1.325 | 2.14 | 22,300 | -1.17 | -40.37% |
3 Years | 15.60 | 17.88 | 1.325 | 12.72 | 769,264 | -13.87 | -88.92% |
5 Years | 30.12 | 49.20 | 1.325 | 18.89 | 2,024,489 | -28.39 | -94.26% |
Cocrystal Pharma Description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). |